Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt is a clinical-stage biotech focused on oncology immunotherapies, making 'Biotech - Oncology' a core investable theme.
|
$9.50M |
$5.08
+0.30%
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$9.12M |
$2.04
+7.94%
|
|
SEED
Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
|
$9.00M |
$1.46
+11.07%
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$8.98M |
$1.25
+6.36%
|
|
EPIX
ESSA Pharma Inc.
Directly describes a biotech company focused on oncology drug development (masofaniten) with no revenue; core business is cancer therapeutics.
|
$8.93M |
$0.20
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$8.78M |
$1.11
|
|
ICU
SeaStar Medical Holding Corporation
QUELIMMUNE represents an immunology therapeutic, aligning with Immunology Therapeutics.
|
$8.50M |
$0.30
-5.00%
|
|
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech's lead asset Annamycin is a cancer drug candidate, placing the company squarely in the Biotech - Oncology category.
|
$8.48M |
$0.28
-23.39%
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$8.46M |
$3.94
+3.68%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$8.30M |
$1.43
-0.35%
|
|
BLRX
BioLineRx Ltd.
BioLineRx's lead oncology asset motixafortide (APHEXDA) places the company squarely in oncology with an approved stem cell mobilization therapy and ongoing cancer indications development.
|
$8.26M |
$3.44
-3.10%
|
|
TSBX
Turnstone Biologics Corp.
Company's core business is oncology-focused biotechnology, including immunotherapy approaches (TIL-based strategies) in solid tumors.
|
$8.21M |
$0.35
|
|
BGLC
BioNexus Gene Lab Corp.
Chemrex pivot to biotech-focused CDMO activities positions it as a Contract Manufacturing Organization.
|
$8.16M |
$4.42
+2.31%
|
|
PAVM
PAVmed Inc.
PAVmed's biopharma expansion targets oncology assets, aligning with Biotech - Oncology.
|
$7.96M |
$0.37
+9.62%
|
|
KTTA
Pasithea Therapeutics Corp.
Pasithea's lead candidate PAS-4.00 is a MEK inhibitor targeting MAPK pathway-driven tumors, aligning with oncology-focused biotech.
|
$7.89M |
$0.95
+95.37%
|
|
EVGN
Evogene Ltd.
Biomica's microbiome therapeutics program (BMC128) targets human health, fitting Immunology Therapeutics within Biotech.
|
$7.71M |
$1.11
+1.36%
|
|
RNAZ
TransCode Therapeutics, Inc.
TransCode Therapeutics operates in biotech oncology, developing cancer therapeutics.
|
$7.69M |
$9.30
+1.25%
|
|
BIXT
Bioxytran, Inc.
ProLectin-M is an oral antiviral candidate; fits the Oral Small Molecule Therapeutics category as a major product line.
|
$7.56M |
$0.09
|
|
PRPH
ProPhase Labs, Inc.
BE-Smart uses a biomarker-based diagnostic panel, aligning with companion diagnostics.
|
$7.52M |
$0.19
+3.45%
|
|
TRIB
Trinity Biotech plc
Includes companion diagnostics/biomarker-guided tests as part of its oncology-focused diagnostic portfolio.
|
$7.51M |
$0.96
+7.45%
|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$7.33M |
$1.33
+4.72%
|
|
APRE
Aprea Therapeutics, Inc.
APRE is an oncology-focused biotech developing cancer therapies, namely DDR inhibitors, which aligns with Biotech - Oncology.
|
$7.28M |
$1.26
+4.13%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics directly develops cancer therapies (oncolytic virus platforms) targeting oncology indications.
|
$7.07M |
$1.49
+6.43%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$7.04M |
$1.24
+3.33%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaCell's core focus is oncology immunotherapies, aligning with Biotech - Oncology.
|
$6.97M |
$10.38
+7.56%
|
|
XAIR
Beyond Air, Inc.
UNO program for solid tumors places Beyond Air in oncology-focused biotech pipelines.
|
$6.95M |
$1.33
-0.37%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
CELZ develops autologous/allogeneic cell therapies (ImmCelz and AlloStem), a core cell therapy business.
|
$6.89M |
$2.67
-2.55%
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$6.77M |
$0.31
+2.35%
|
|
DQWS
DSwiss, Inc.
DQWS provides turnkey OEM/ODM contract manufacturing services for health care, beauty, and nutraceutical products.
|
$6.62M |
$0.03
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$6.56M |
$4.71
-18.60%
|
|
BMRA
Biomerica, Inc.
Offers Contract Manufacturing services with notable growth, i.e., contract manufacturing revenue stream.
|
$6.53M |
$2.33
-2.51%
|
|
ALZN
Alzamend Neuro, Inc.
Company's pipeline includes Alzheimer's disease therapeutics (ALZN002) and a focused strategy on Alzheimer's treatment.
|
$6.49M |
$2.25
+4.91%
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$6.45M |
$1.89
+4.72%
|
|
KALA
KALA BIO, Inc.
KPI-012 is a mesenchymal stem cell secretome (MSC-S) therapy, aligning with Biotech - Cell Therapy.
|
$6.39M |
$0.94
+47.19%
|
|
SBFM
Sunshine Biopharma, Inc.
SBFM's Nora Pharma operates a growing Canadian generic prescription drug business.
|
$6.38M |
$1.42
+1.80%
|
Showing page 23 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
